0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adalimumab Injection Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-10E14242
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Adalimumab Injection Market Research Report 2023
BUY CHAPTERS

Global Adalimumab Injection Market Research Report 2025

Code: QYRE-Auto-10E14242
Report
May 2025
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Adalimumab Injection Market Size

The global market for Adalimumab Injection was valued at US$ 1003 million in the year 2024 and is projected to reach a revised size of US$ 1461 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Adalimumab Injection Market

Adalimumab Injection Market

North American market for Adalimumab Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Adalimumab Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Adalimumab Injection include AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd., Hisun Biopharmaceutical, Innovent Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Adalimumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Injection.
The Adalimumab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adalimumab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Adalimumab Injection Market Report

Report Metric Details
Report Name Adalimumab Injection Market
Accounted market size in year US$ 1003 million
Forecasted market size in 2031 US$ 1461 million
CAGR 5.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 40mg/0.8ml
  • 20mg/0.4ml
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd., Hisun Biopharmaceutical, Innovent Biologics, Mylan, Zydus Group, Boehringer Ingelheim, Jiangsu Chia Tai-Tianqing Pharmaceutical, Shanghai Henlius Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Adalimumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Adalimumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Adalimumab Injection Market growing?

Ans: The Adalimumab Injection Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Adalimumab Injection Market size in 2031?

Ans: The Adalimumab Injection Market size in 2031 will be US$ 1461 million.

Who are the main players in the Adalimumab Injection Market report?

Ans: The main players in the Adalimumab Injection Market are AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd., Hisun Biopharmaceutical, Innovent Biologics, Mylan, Zydus Group, Boehringer Ingelheim, Jiangsu Chia Tai-Tianqing Pharmaceutical, Shanghai Henlius Biotech

What are the Application segmentation covered in the Adalimumab Injection Market report?

Ans: The Applications covered in the Adalimumab Injection Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Adalimumab Injection Market report?

Ans: The Types covered in the Adalimumab Injection Market report are 40mg/0.8ml, 20mg/0.4ml

Recommended Reports

Injection Drug Markets

Autoimmune & Immune

Injectable Delivery Tech

1 Adalimumab Injection Market Overview
1.1 Product Definition
1.2 Adalimumab Injection by Type
1.2.1 Global Adalimumab Injection Market Value Comparison by Type (2024 VS 2031)
1.2.2 40mg/0.8ml
1.2.3 20mg/0.4ml
1.3 Adalimumab Injection by Application
1.3.1 Global Adalimumab Injection Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Adalimumab Injection Market Size Estimates and Forecasts
1.4.1 Global Adalimumab Injection Revenue 2020-2031
1.4.2 Global Adalimumab Injection Sales 2020-2031
1.4.3 Global Adalimumab Injection Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Adalimumab Injection Market Competition by Manufacturers
2.1 Global Adalimumab Injection Sales Market Share by Manufacturers (2020-2025)
2.2 Global Adalimumab Injection Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Adalimumab Injection Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Adalimumab Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adalimumab Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab Injection, Product Type & Application
2.7 Global Key Manufacturers of Adalimumab Injection, Date of Enter into This Industry
2.8 Global Adalimumab Injection Market Competitive Situation and Trends
2.8.1 Global Adalimumab Injection Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Adalimumab Injection Players Market Share by Revenue
2.8.3 Global Adalimumab Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Adalimumab Injection Market Scenario by Region
3.1 Global Adalimumab Injection Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Adalimumab Injection Sales by Region: 2020-2031
3.2.1 Global Adalimumab Injection Sales by Region: 2020-2025
3.2.2 Global Adalimumab Injection Sales by Region: 2026-2031
3.3 Global Adalimumab Injection Revenue by Region: 2020-2031
3.3.1 Global Adalimumab Injection Revenue by Region: 2020-2025
3.3.2 Global Adalimumab Injection Revenue by Region: 2026-2031
3.4 North America Adalimumab Injection Market Facts & Figures by Country
3.4.1 North America Adalimumab Injection Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Adalimumab Injection Sales by Country (2020-2031)
3.4.3 North America Adalimumab Injection Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adalimumab Injection Market Facts & Figures by Country
3.5.1 Europe Adalimumab Injection Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Adalimumab Injection Sales by Country (2020-2031)
3.5.3 Europe Adalimumab Injection Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Adalimumab Injection Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Adalimumab Injection Sales by Region (2020-2031)
3.6.3 Asia Pacific Adalimumab Injection Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adalimumab Injection Market Facts & Figures by Country
3.7.1 Latin America Adalimumab Injection Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Adalimumab Injection Sales by Country (2020-2031)
3.7.3 Latin America Adalimumab Injection Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adalimumab Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab Injection Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Adalimumab Injection Sales by Country (2020-2031)
3.8.3 Middle East and Africa Adalimumab Injection Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adalimumab Injection Sales by Type (2020-2031)
4.1.1 Global Adalimumab Injection Sales by Type (2020-2025)
4.1.2 Global Adalimumab Injection Sales by Type (2026-2031)
4.1.3 Global Adalimumab Injection Sales Market Share by Type (2020-2031)
4.2 Global Adalimumab Injection Revenue by Type (2020-2031)
4.2.1 Global Adalimumab Injection Revenue by Type (2020-2025)
4.2.2 Global Adalimumab Injection Revenue by Type (2026-2031)
4.2.3 Global Adalimumab Injection Revenue Market Share by Type (2020-2031)
4.3 Global Adalimumab Injection Price by Type (2020-2031)
5 Segment by Application
5.1 Global Adalimumab Injection Sales by Application (2020-2031)
5.1.1 Global Adalimumab Injection Sales by Application (2020-2025)
5.1.2 Global Adalimumab Injection Sales by Application (2026-2031)
5.1.3 Global Adalimumab Injection Sales Market Share by Application (2020-2031)
5.2 Global Adalimumab Injection Revenue by Application (2020-2031)
5.2.1 Global Adalimumab Injection Revenue by Application (2020-2025)
5.2.2 Global Adalimumab Injection Revenue by Application (2026-2031)
5.2.3 Global Adalimumab Injection Revenue Market Share by Application (2020-2031)
5.3 Global Adalimumab Injection Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Adalimumab Injection Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Company Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Amgen Adalimumab Injection Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Sandoz
6.3.1 Sandoz Company Information
6.3.2 Sandoz Description and Business Overview
6.3.3 Sandoz Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sandoz Adalimumab Injection Product Portfolio
6.3.5 Sandoz Recent Developments/Updates
6.4 Fresenius Kabi
6.4.1 Fresenius Kabi Company Information
6.4.2 Fresenius Kabi Description and Business Overview
6.4.3 Fresenius Kabi Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Fresenius Kabi Adalimumab Injection Product Portfolio
6.4.5 Fresenius Kabi Recent Developments/Updates
6.5 Biogen
6.5.1 Biogen Company Information
6.5.2 Biogen Description and Business Overview
6.5.3 Biogen Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Biogen Adalimumab Injection Product Portfolio
6.5.5 Biogen Recent Developments/Updates
6.6 Celltrion
6.6.1 Celltrion Company Information
6.6.2 Celltrion Description and Business Overview
6.6.3 Celltrion Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Celltrion Adalimumab Injection Product Portfolio
6.6.5 Celltrion Recent Developments/Updates
6.7 Cadila Pharmaceuticals
6.7.1 Cadila Pharmaceuticals Company Information
6.7.2 Cadila Pharmaceuticals Description and Business Overview
6.7.3 Cadila Pharmaceuticals Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Cadila Pharmaceuticals Adalimumab Injection Product Portfolio
6.7.5 Cadila Pharmaceuticals Recent Developments/Updates
6.8 Bio-Thera Solutions, Ltd.
6.8.1 Bio-Thera Solutions, Ltd. Company Information
6.8.2 Bio-Thera Solutions, Ltd. Description and Business Overview
6.8.3 Bio-Thera Solutions, Ltd. Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio
6.8.5 Bio-Thera Solutions, Ltd. Recent Developments/Updates
6.9 Hisun Biopharmaceutical
6.9.1 Hisun Biopharmaceutical Company Information
6.9.2 Hisun Biopharmaceutical Description and Business Overview
6.9.3 Hisun Biopharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Hisun Biopharmaceutical Adalimumab Injection Product Portfolio
6.9.5 Hisun Biopharmaceutical Recent Developments/Updates
6.10 Innovent Biologics
6.10.1 Innovent Biologics Company Information
6.10.2 Innovent Biologics Description and Business Overview
6.10.3 Innovent Biologics Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Innovent Biologics Adalimumab Injection Product Portfolio
6.10.5 Innovent Biologics Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Company Information
6.11.2 Mylan Description and Business Overview
6.11.3 Mylan Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Mylan Adalimumab Injection Product Portfolio
6.11.5 Mylan Recent Developments/Updates
6.12 Zydus Group
6.12.1 Zydus Group Company Information
6.12.2 Zydus Group Description and Business Overview
6.12.3 Zydus Group Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Zydus Group Adalimumab Injection Product Portfolio
6.12.5 Zydus Group Recent Developments/Updates
6.13 Boehringer Ingelheim
6.13.1 Boehringer Ingelheim Company Information
6.13.2 Boehringer Ingelheim Description and Business Overview
6.13.3 Boehringer Ingelheim Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Boehringer Ingelheim Adalimumab Injection Product Portfolio
6.13.5 Boehringer Ingelheim Recent Developments/Updates
6.14 Jiangsu Chia Tai-Tianqing Pharmaceutical
6.14.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information
6.14.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Description and Business Overview
6.14.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio
6.14.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates
6.15 Shanghai Henlius Biotech
6.15.1 Shanghai Henlius Biotech Company Information
6.15.2 Shanghai Henlius Biotech Description and Business Overview
6.15.3 Shanghai Henlius Biotech Adalimumab Injection Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Shanghai Henlius Biotech Adalimumab Injection Product Portfolio
6.15.5 Shanghai Henlius Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab Injection Industry Chain Analysis
7.2 Adalimumab Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab Injection Production Mode & Process Analysis
7.4 Adalimumab Injection Sales and Marketing
7.4.1 Adalimumab Injection Sales Channels
7.4.2 Adalimumab Injection Distributors
7.5 Adalimumab Injection Customer Analysis
8 Adalimumab Injection Market Dynamics
8.1 Adalimumab Injection Industry Trends
8.2 Adalimumab Injection Market Drivers
8.3 Adalimumab Injection Market Challenges
8.4 Adalimumab Injection Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Adalimumab Injection Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Adalimumab Injection Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Adalimumab Injection Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Adalimumab Injection Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Adalimumab Injection Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Adalimumab Injection Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Adalimumab Injection Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Adalimumab Injection Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Adalimumab Injection, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Adalimumab Injection, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Adalimumab Injection, Product Type & Application
 Table 12. Global Key Manufacturers of Adalimumab Injection, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Adalimumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab Injection as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Adalimumab Injection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Adalimumab Injection Sales by Region (2020-2025) & (K Units)
 Table 18. Global Adalimumab Injection Sales Market Share by Region (2020-2025)
 Table 19. Global Adalimumab Injection Sales by Region (2026-2031) & (K Units)
 Table 20. Global Adalimumab Injection Sales Market Share by Region (2026-2031)
 Table 21. Global Adalimumab Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Adalimumab Injection Revenue Market Share by Region (2020-2025)
 Table 23. Global Adalimumab Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Adalimumab Injection Revenue Market Share by Region (2026-2031)
 Table 25. North America Adalimumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Adalimumab Injection Sales by Country (2020-2025) & (K Units)
 Table 27. North America Adalimumab Injection Sales by Country (2026-2031) & (K Units)
 Table 28. North America Adalimumab Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Adalimumab Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Adalimumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Adalimumab Injection Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Adalimumab Injection Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Adalimumab Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Adalimumab Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Adalimumab Injection Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Adalimumab Injection Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Adalimumab Injection Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Adalimumab Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Adalimumab Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Adalimumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Adalimumab Injection Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Adalimumab Injection Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Adalimumab Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Adalimumab Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Adalimumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Adalimumab Injection Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Adalimumab Injection Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Adalimumab Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Adalimumab Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Adalimumab Injection Sales (K Units) by Type (2020-2025)
 Table 51. Global Adalimumab Injection Sales (K Units) by Type (2026-2031)
 Table 52. Global Adalimumab Injection Sales Market Share by Type (2020-2025)
 Table 53. Global Adalimumab Injection Sales Market Share by Type (2026-2031)
 Table 54. Global Adalimumab Injection Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Adalimumab Injection Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Adalimumab Injection Revenue Market Share by Type (2020-2025)
 Table 57. Global Adalimumab Injection Revenue Market Share by Type (2026-2031)
 Table 58. Global Adalimumab Injection Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Adalimumab Injection Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Adalimumab Injection Sales (K Units) by Application (2020-2025)
 Table 61. Global Adalimumab Injection Sales (K Units) by Application (2026-2031)
 Table 62. Global Adalimumab Injection Sales Market Share by Application (2020-2025)
 Table 63. Global Adalimumab Injection Sales Market Share by Application (2026-2031)
 Table 64. Global Adalimumab Injection Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Adalimumab Injection Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Adalimumab Injection Revenue Market Share by Application (2020-2025)
 Table 67. Global Adalimumab Injection Revenue Market Share by Application (2026-2031)
 Table 68. Global Adalimumab Injection Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Adalimumab Injection Price (US$/Unit) by Application (2026-2031)
 Table 70. AbbVie Company Information
 Table 71. AbbVie Description and Business Overview
 Table 72. AbbVie Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AbbVie Adalimumab Injection Product
 Table 74. AbbVie Recent Developments/Updates
 Table 75. Amgen Company Information
 Table 76. Amgen Description and Business Overview
 Table 77. Amgen Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Amgen Adalimumab Injection Product
 Table 79. Amgen Recent Developments/Updates
 Table 80. Sandoz Company Information
 Table 81. Sandoz Description and Business Overview
 Table 82. Sandoz Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Sandoz Adalimumab Injection Product
 Table 84. Sandoz Recent Developments/Updates
 Table 85. Fresenius Kabi Company Information
 Table 86. Fresenius Kabi Description and Business Overview
 Table 87. Fresenius Kabi Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Fresenius Kabi Adalimumab Injection Product
 Table 89. Fresenius Kabi Recent Developments/Updates
 Table 90. Biogen Company Information
 Table 91. Biogen Description and Business Overview
 Table 92. Biogen Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Biogen Adalimumab Injection Product
 Table 94. Biogen Recent Developments/Updates
 Table 95. Celltrion Company Information
 Table 96. Celltrion Description and Business Overview
 Table 97. Celltrion Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Celltrion Adalimumab Injection Product
 Table 99. Celltrion Recent Developments/Updates
 Table 100. Cadila Pharmaceuticals Company Information
 Table 101. Cadila Pharmaceuticals Description and Business Overview
 Table 102. Cadila Pharmaceuticals Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Cadila Pharmaceuticals Adalimumab Injection Product
 Table 104. Cadila Pharmaceuticals Recent Developments/Updates
 Table 105. Bio-Thera Solutions, Ltd. Company Information
 Table 106. Bio-Thera Solutions, Ltd. Description and Business Overview
 Table 107. Bio-Thera Solutions, Ltd. Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Bio-Thera Solutions, Ltd. Adalimumab Injection Product
 Table 109. Bio-Thera Solutions, Ltd. Recent Developments/Updates
 Table 110. Hisun Biopharmaceutical Company Information
 Table 111. Hisun Biopharmaceutical Description and Business Overview
 Table 112. Hisun Biopharmaceutical Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Hisun Biopharmaceutical Adalimumab Injection Product
 Table 114. Hisun Biopharmaceutical Recent Developments/Updates
 Table 115. Innovent Biologics Company Information
 Table 116. Innovent Biologics Description and Business Overview
 Table 117. Innovent Biologics Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Innovent Biologics Adalimumab Injection Product
 Table 119. Innovent Biologics Recent Developments/Updates
 Table 120. Mylan Company Information
 Table 121. Mylan Description and Business Overview
 Table 122. Mylan Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Mylan Adalimumab Injection Product
 Table 124. Mylan Recent Developments/Updates
 Table 125. Zydus Group Company Information
 Table 126. Zydus Group Description and Business Overview
 Table 127. Zydus Group Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Zydus Group Adalimumab Injection Product
 Table 129. Zydus Group Recent Developments/Updates
 Table 130. Boehringer Ingelheim Company Information
 Table 131. Boehringer Ingelheim Description and Business Overview
 Table 132. Boehringer Ingelheim Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Boehringer Ingelheim Adalimumab Injection Product
 Table 134. Boehringer Ingelheim Recent Developments/Updates
 Table 135. Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information
 Table 136. Jiangsu Chia Tai-Tianqing Pharmaceutical Description and Business Overview
 Table 137. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product
 Table 139. Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates
 Table 140. Shanghai Henlius Biotech Company Information
 Table 141. Shanghai Henlius Biotech Description and Business Overview
 Table 142. Shanghai Henlius Biotech Adalimumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Shanghai Henlius Biotech Adalimumab Injection Product
 Table 144. Shanghai Henlius Biotech Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Adalimumab Injection Distributors List
 Table 148. Adalimumab Injection Customers List
 Table 149. Adalimumab Injection Market Trends
 Table 150. Adalimumab Injection Market Drivers
 Table 151. Adalimumab Injection Market Challenges
 Table 152. Adalimumab Injection Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Adalimumab Injection
 Figure 2. Global Adalimumab Injection Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Adalimumab Injection Market Share by Type: 2024 & 2031
 Figure 4. 40mg/0.8ml Product Picture
 Figure 5. 20mg/0.4ml Product Picture
 Figure 6. Global Adalimumab Injection Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Adalimumab Injection Market Share by Application: 2024 & 2031
 Figure 8. Hospitals
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Adalimumab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Adalimumab Injection Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Adalimumab Injection Sales (2020-2031) & (K Units)
 Figure 14. Global Adalimumab Injection Average Price (US$/Unit) & (2020-2031)
 Figure 15. Adalimumab Injection Report Years Considered
 Figure 16. Adalimumab Injection Sales Share by Manufacturers in 2024
 Figure 17. Global Adalimumab Injection Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Adalimumab Injection Players: Market Share by Revenue in Adalimumab Injection in 2024
 Figure 19. Adalimumab Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Adalimumab Injection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Adalimumab Injection Sales Market Share by Country (2020-2031)
 Figure 22. North America Adalimumab Injection Revenue Market Share by Country (2020-2031)
 Figure 23. United States Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Adalimumab Injection Sales Market Share by Country (2020-2031)
 Figure 26. Europe Adalimumab Injection Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Adalimumab Injection Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Adalimumab Injection Revenue Market Share by Region (2020-2031)
 Figure 34. China Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Adalimumab Injection Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Adalimumab Injection Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Adalimumab Injection Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Adalimumab Injection Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Adalimumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Adalimumab Injection by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Adalimumab Injection by Type (2020-2031)
 Figure 53. Global Adalimumab Injection Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Adalimumab Injection by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Adalimumab Injection by Application (2020-2031)
 Figure 56. Global Adalimumab Injection Price (US$/Unit) by Application (2020-2031)
 Figure 57. Adalimumab Injection Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS